Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Interest & Investment Income (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Interest & Investment Income for 4 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 54.56% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, down 43.51% year-over-year, with the annual reading at $7.3 million for FY2025, 43.52% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.3 million at Century Therapeutics, down from $1.6 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $3.6 million in Q2 2024, with the low at $706000.0 in Q2 2022.
  • Average Interest & Investment Income over 4 years is $2.5 million, with a median of $2.8 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income skyrocketed 333.14% in 2023, then plummeted 54.56% in 2025.
  • Over 4 years, Interest & Investment Income stood at $1.4 million in 2022, then skyrocketed by 148.76% to $3.5 million in 2023, then fell by 17.92% to $2.9 million in 2024, then tumbled by 54.56% to $1.3 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $1.3 million, $1.6 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.